Mitokinin
Dr. Ditsworth is a Senior Scientist at Mitokinin and Team Leader of the Cell Biology group. An accomplished cell biologist with expertise in neurobiology and therapeutic development, Dr. Ditsworth brings nearly two decades of research experience to bear in overseeing the Company’s cell-based assays and PINK1/Parkin pathway investigations. In addition to leading her internal team, Dr. Ditsworth also coordinates the Company’s cell line development activities with outside CRO partners.
Dr. Ditsworth received her Ph.D in the lab of Craig Thompson at the University of Pennsylvania, where she focused on DNA damage response pathways in cancer chemotherapy. She then completed her Postdoctoral training in the lab of Don Cleveland at UCSD, during which time she demonstrated the importance of non-cell autonomous mechanisms to the progression of ALS.
This person is not in any teams
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.